AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

UBS has upgraded AstraZeneca PLC (LSE:AZN) to a 'neutral' rating from 'sell' while maintaining its 12-month price target of 11,300 pence. The change follows a 24% drop in AZ's share price over three months, triggered by ongoing investigations in China and disappointing trial data for its cancer drug Dato-DXd.

AstraZeneca upgraded by leading investment bank, but challenges remain - here's why

AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention of Wes Streeting, the health secretary.

AstraZeneca hits out at NICE block to breast cancer drug

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

In its latest outlook for 2025, Goldman Sachs is urging investors to “buy British” as undervalued UK stocks offer an attractive opportunity in Europe's otherwise tepid equity market. The bank highlights that UK shares, particularly those with a domestic focus, are trading at a discount compared to other European and US markets.

Goldman: Buy British for better returns in 2025

NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors, Contact Levi & Korsinsky For Details

GRAIL Inc

MENLO PARK, Calif. , Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC.

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy?

Collaboration to harness Lunit SCOPE Genotype Predictor for rapid and convenient prediction of non-small cell lung cancer driver mutations SEOUL, South Korea , Nov. 18, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a strategic collaboration with AstraZeneca, a leading pharmaceutical company, to develop AI-powered digital pathology solutions. The solution in focus is Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor (EGFR) mutations.

Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC

BioNTech SE

Eli Lilly

Moderna

Novavax

Novo Nordisk

Pfizer

In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services.

Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head

GlaxoSmithKline

Inovio Pharmaceuticals

Merck

Sanofi

Valneva SE

Some large European and U.S. vaccine maker stocks have fallen in reaction to Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services.

European And US Vaccine Stocks Are Under Pressure - Here's WHy

Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK

Pharma shares hit as Trump picks RFK Jr to lead health department

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - AZN

AstraZeneca just released some encouraging data about its weight loss drug candidates.

Is AstraZeneca a Buy as It Eyes the Weight Loss Market?

AstraZeneca PLC aims for $80 billion revenue by 2030, driven by strong growth in oncology, biopharmaceuticals, and rare diseases, despite recent share price declines. The company's weight management pipeline, including AZD5004 and AZD6234, shows significant growth potential, especially with strategic hires and advancements in clinical trials. Financial performance in Q3 2024 was robust, with a 21% revenue increase, supporting the company's ambitious long-term goals despite increased operating expenses.

AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity

AstraZeneca said it is doubling down on its investment in its U.S. business. Meanwhile, General Catalyst has agreed to purchase Summa Health for $485 million.

Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time this year.

AstraZeneca Beats on Q3 Earnings, Ups 2024 View, to Invest $3.5B in US

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

Levi & Korsinsky Announces an Investigation on Behalf of AstraZeneca PLC (AZN) Shareholders Who May Have Been Affected by Fraud

AstraZeneca PLC (NASDAQ:AZN ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Aradhana Sarin - Executive Director and CFO Dave Fredrickson - Executive Vice President, Oncology Business Susan Galbraith - Executive Vice President, Oncology Research and Development Ruud Dobber - Executive Vice President and President, BioPharmaceuticals Sharon Barr - Executive Vice President, BioPharmaceuticals Research and Development Marc Dunoyer - Chief Executive Officer, Alexion and CSO, AstraZeneca Conference Call Participants James Gordon - JPMorgan Richard Parkes - BNP Paribas Exane Sachin Jain - Bank of America Christopher Uhde - SEB Gonzalo Artiach - Danske Bank Steve Scala - Cowen Rajan Sharma - Goldman Sachs Etzer Darout - BMO Simon Baker - Redburn Emmanuel Papadakis - Deutsche Bank Mattias Haggblom - Handelsbanken Eric Le Berrigaud - Stifel Rajesh Kumar - HSBC Gonzalo Artiach - Danske Bank Peter Welford - Jefferies Luisa Hector - Berenberg Capital Markets Emily Field - Barclays Operator Good morning to those joining from the U.S., good afternoon to those in the U.K. and Central Europe, and good evening to those listening in Asia. Welcome ladies and gentlemen to AstraZeneca's Nine Months and Q3 Results 2024 Webinar for Investors and Analysts.

AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript

British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the end of 2026.

AstraZeneca Lifts Outlook, Plans $3.5B US Investment

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q3 Earnings

AstraZeneca Plc AZN reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.

AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, but AstraZeneca stock slipped amid a criminal probe in China. The post AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beat appeared first on Investor's Business Daily.

AstraZeneca Stock Dives As China's Criminal Probe Rattles Its Third-Quarter Beat

London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with the government over incentives continue.

AstraZeneca: 450 million pound investment in UK under review amid talks with govt

AstraZeneca PLC (LSE:AZN) chief executive Pascal Soriot has signalled the company is taking a criminal probe into its Chinese business “very seriously”. Soriot on Tuesday said AstraZeneca would “fully cooperate” with Chinese authorities over the case, which has seen China president Leon Wang detained.

AstraZeneca boss says China arrests taken ‘very seriously'

AstraZeneca's China president Leon Wang, who was detained last month by Chinese authorities, is in touch with a lawyer but the company has very little information about the case, its CEO said on Tuesday.

News for AstraZeneca Stock (AZN)